Myrexis to Present at 10th Annual JMP Securities Research Conference
May 03, 2011 16:00 ET
|
Myrexis, Inc.
SALT LAKE CITY, May 3, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced that Adrian...
Myrexis to Hold Conference Call to Discuss Fiscal Third Quarter 2011 Financial Results
April 28, 2011 16:00 ET
|
Myrexis, Inc.
SALT LAKE CITY, April 28, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced it will...
Myrexis Presents Data on Cancer Metabolism Inhibitor Program at 102nd AACR Annual Meeting
April 05, 2011 08:00 ET
|
Myrexis, Inc.
SALT LAKE CITY, April 5, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced it...
Myrexis Presents Data on Hsp90 Inhibitor Program at 102nd AACR Annual Meeting
April 05, 2011 08:00 ET
|
Myrexis, Inc.
Potential for Combination With Other Targeted Cancer Therapies
Prodrug With Improved Characteristics Demonstrates Equivalent Efficacy
Evidence of Biological Activity in Patients
SALT LAKE...
Myrexis Reorganizes to Align Resources With Current Pipeline
March 29, 2011 12:15 ET
|
Myrexis, Inc.
SALT LAKE CITY, March 29, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced a...
Myrexis to Provide Update on Heat Shock Protein 90 and Cancer Metabolism Inhibitor Programs at 102nd Annual Meeting of American Association for Cancer Research
March 17, 2011 16:00 ET
|
Myrexis, Inc.
SALT LAKE CITY, March 17, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
Myrexis to Present at 10th Annual Needham Healthcare Conference
March 16, 2011 16:00 ET
|
Myrexis, Inc.
SALT LAKE CITY, March 16, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
Myrexis Reports Second Quarter Fiscal 2011 Financial Results
February 09, 2011 16:15 ET
|
Myrexis, Inc.
AzixaTM Two-Arm Phase 2b Study in Glioblastoma Initiated
Conference Call Today at 4:30pm EST
Upcoming Events
Report Phase 2 monotherapy results in recurrent glioblastoma multiforme (GBM)...
Myrexis Announces Azixa(TM) Clinical Data Publications
February 03, 2011 09:00 ET
|
Myrexis, Inc.
Phase 1 Clinical Data Published by Molecular Cancer Therapeutics
Pre-Clinical, Phase 1 and 2 Clinical Data Review Published by Drugs of the Future
SALT LAKE CITY, Feb. 3, 2011 (GLOBE NEWSWIRE)...
Myrexis to Hold Conference Call to Discuss Fiscal Second Quarter 2011 Financial Results
February 01, 2011 09:00 ET
|
Myrexis, Inc.
SALT LAKE CITY, Feb. 1, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...